UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Want to earn the most rewards on your purchases? Check out our top credit card picks that provide outstanding reward programs.
28,031 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Gold is leading gains in early 2026, while silver remains volatile. Analysts say the evolving ETF landscape is paving...
A high-stakes earnings year and a single insider trade create a nuanced picture for ANI Pharmaceuticals. This guide b...
When markets punish uncertainty, contrarian investors can find hidden upside. This article highlights three strugglin...
AI market storms have created massive wealth for early believers. Explore a standout name that became this stock near...
Two popular names in tech and space economics spark a debate: should you buy SpaceX stock while selling Micron stock,...
Is crypto a solid investment in 2026? This guide weighs potential gains against volatility, regulatory shifts, and ri...
Spotting a strong real estate market isn’t guesswork. By watching a few proven metrics that matter: spot—rent growth,...
Portillo's has faced growth and branding challenges that threaten its future. This guide breaks down what a comeback ...
A hedge fund made a sizable new bet on Centuri Holdings, disclosed in an SEC filing. This article breaks down the num...
A new science council linked to Trump signals a stronger link between AI and crypto policy. This morning minute exami...
Magnolia (MGY) is delivering a pivotal Q1 2026 performance that tests the durability of its business model. This arti...